My Treatment Approach: Evolving Treatment Strategies in Metastatic Melanoma

Nikhil Khushalani, MD, offers a brief overview of the landscape surrounding melanoma, encompassing key aspects such as incidence rates and prognosis.

Nikhil Khushalani, MD, explores the significance of biomarker testing in melanoma, emphasizing the pivotal role of BRAF in understanding and managing this type of skin cancer.

Nikhil Khushalani, MD, provides a thorough exploration of the current treatment landscape in adjuvant therapy for melanoma, presenting insights into advancing strategies and developments in the field, while also discussing key findings from the CheckMate 238 and KEYNOTE-054 trials.

Nikhil Khushalani, MD, delves into the role of combination immunotherapy strategies for melanoma in the adjuvant setting, providing insights into the specific details and outcomes of the IMMUNED trial.

Nikhil Khushalani, MD, navigates the challenges associated with predicting and mitigating adverse events in adjuvant immunotherapy, offering valuable insights into strategies for addressing potential complications in this treatment approach.

Nikhil Khushalani, MD, examines immunotherapy resistance in melanoma treatment, providing valuable insights into navigating challenges and its impact on treatment decisions.

A panel of oncology experts explores the intricate balance between maintaining quality of life and managing toxicity in adjuvant immunotherapy for melanoma.

Afreen Shariff, MD, MBBS, introduces case 1, involving a 55-year-old man with stage IIIB melanoma who develops immunotherapy-induced diabetes.

Afreen Shariff, MD, MBBS, discusses managing immunotherapy-related diabetes in melanoma, emphasizing the critical need to detect sudden changes in blood sugar levels and advocating for a multidisciplinary approach.

Afreen Shariff, MD, MBBS, examines the surveillance and management of immunotherapy-induced adrenal insufficiency in the context of melanoma, underscoring the importance of maintaining a heightened awareness for early detection.

Javid Moslehi, MD, presents Case 2, highlighting a 63-year-old female patient with metastatic melanoma on dual immunotherapy, illustrating treatment-related myocarditis and emphasizing key aspects of immunotherapy-induced cardiac toxicities.

Javid Moslehi, MD, shares expert perspectives on the diagnosis and management of immunotherapy-related myocarditis.

Javid Moslehi, MD provides expert insights into baseline and surveillance cardiac testing for individuals receiving immunotherapy.

A panel of oncology experts explore the challenges in treating patients with immunotherapy-related toxicities using corticosteroids.

A group of oncology experts provide forward-looking perspectives and clinical insights in the treatment of melanoma.